Pharma's Market
SPECIAL REPORT
MOST SHARED
- Nielsen Ratings Coming to Video Games
- Confessions of a Black Friday Shopper
- 'New Moon' Midnight Showings Earn Record $26.3 Million
- Time Lapse World Series Is A Great Play
- The Week Ahead
- Oil Next Week
- Hershey Mulls $17 Billion Bid for Cadbury: Source
- Hot Topics at TEDMED
- Latest Bullish Sign for Gold: Central Banks Are Big Buyers
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
- Holiday Tipping: Who And How Much
- Deep Discounts Should Make It a Very Tech-y Holiday
- Credit Markets on Edge About When Fed Will Raise Rates
- Bove: Expect Goldman To Increase Dividend Meaningfully
- Bullish Sign for Gold: Central Banks Are Big Buyers
- Victoria's Secret Hopes to Rekindle Desire for Lingerie
- High Roller Sues Harrah's for Lost Millions
- Wall Street Jobs Slow to Return Despite Record Profits
- Big Shareholders Ask Goldman to Cut Bonuses: Report
- Buying an Expensive House? Government Can Help
- Review: What It's Like to Drive the New Chevy Volt
PHARMA'S MARKET VIDEO
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009
Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
RSS FEED
Text Size 
CNBC Correspondent
On a day when the market is in full-tilt rally mode on the GDP number, shares of Dow component Merck [MRK
Loading...
()
] and the company it's buying, Schering-Plough [SGP
Loading...
()
], are sliding. So, what gives?
Well, Bernstein analyst Dr. Tim Anderson put out a MRK-SGP research note this morning titled, "Caveat Emptor," and he did a voicemail blast to clients this morning saying he was "sounding the alarm bells once again."
He's writing and talking about the upcoming presentation of data from a study called "Arbiter 6" comparing MRK and SGP's cholesterol-fighter Zetia to Niaspan from Abbott Labs [ABT
Loading...
()
]. Zetia is also used to make Vytorin along with the statin Zocor. They're big-selling drugs. Researchers will unveil the study results in a so-called "late-breaking clinical trial" session at the American Heart Association's annual meeting in Orlando on Monday, November 16th, at 10:45 a.m. ET. A "late breaker" is prominent, prestigious status that scientific and medical meetings typically grant to big, important studies. They're often done in the biggest convention hall before the largest audience.
Dr. Anderson also says the study will be published simultaneously in a major medical journal, most likely the "New England Journal of Medicine," along with an editorial or two. And he says one of the opinion pieces will be "pretty scathing by a well-known critic." Any guesses? Hmm, lemme think.
Dr. Anderson doesn't think there's anything, as he put it, "truly wrong" with Zetia or Vytorin, but for whatever reason he believes the drugs are "being attacked by some pretty fierce critics." Long-term he still likes Merck together with Schering, but in the near-term he says, "Buyer beware."
On Merck's most recent conference call company officials were already revving up the spin machine. They promised that they will be at AHA in full force messaging docs, so-called key opinion leaders and, of course, the media. I wonder if they'll send the big guns to talk to us.
Disclosures: Someone who lives with one of the Bernstein pharma researchers owns Merck stock. And a part of Bernstein owns at least one percent of MRK and SGP shares.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes